Title: Identification of novel human proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors using a cell-based high-throughput screening assay
Abstract: Aim: The abnormality of lipoprotein is the major risk factor for cardiovascular disease. In clinical treatment, statins are regarded as currently recommended first-line treatments. For hypercholesterolemic individuals in whom adequate LDL reduction cannot be achieved with statins or for those who are statin intolerant, alternative therapeutic option has been made possible by identification of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a drug target. This protein plays an important role in regulating the degradation of hepatic LDLRs. In our study, we aim to identify novel chemical compounds that target PCSK9, then improve the level of LDLR, thereby regulating the level of LDLC.
Publication Year: 2017
Publication Date: 2017-08-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot